The EMF Toxicity Epidemic - Protection and Treatment - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Etiological Pathways Toward Autism and Diversities of Treatments: From Unimodal to Multidimensional Approaches

Neuropsychoanalysis
February 2016
http://www.tandfonline.com/doi/abs/10.1080/15294145.2016.1156388

Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.